Pimagedine

Last updated
Pimagedine
Skeletal formula of a pimagedine Aminoguanidin.svg
Skeletal formula of a pimagedine
Spacefill model of a pimagedine Aminoguanidine sf.png
Spacefill model of a pimagedine
Names
IUPAC name
2-Aminoguanidine
Other names
  • Aminoguanidine
  • Guanyl hydrazine
  • Hydrazinecarboximidamide
  • Imino semicarbazide
  • Monoaminoguanidine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.001.076 OOjs UI icon edit-ltr-progressive.svg
KEGG
PubChem CID
UNII
  • InChI=1S/CH6N4/c2-1(3)5-4/h1,4H,2-3H2 X mark.svgN
    Key: DRCHNMARIZRTKI-UHFFFAOYSA-N X mark.svgN
  • NC(N)N=N
Properties
CH6N4
Molar mass 74.085 g/mol
Density 1.72 g/ml
Boiling point 261 °C (502 °F; 534 K)
log P −1.475
Related compounds
Related compounds
 Guanidine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug. [1] Pimagedine functions as an inhibitor of diamine oxidase and nitric oxide synthase. It acts to reduce levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, glyoxal, methylglyoxal, and related dicarbonyls. These reactive species are converted to less reactive heterocycles by this condensation reaction.

Contents

History

Pimagedine was under development as a drug for kidney diseases by the pharmaceutical company Alteon (now known Synvista Therapeutics Inc.) that was founded in 1986. [2] In 1987, Alteon acquired a license to intellectual property relating to AGE inhibition from Rockefeller University. [3] In 1989, Alteon and Marion Merrell Dow Inc (MMD) entered into a joint development program for pimagedine. [4] In 1992, Alteon licensed a patent from Rockefeller University relating to the use of pimagedine to inhibit AGE formation. [3] In 1995, Hoechst AG (now Sanofi-Aventis) acquired MMD and subsequently terminated its agreement with Alteon, which led Alteon to stop clinical trials, which caused some controversy. [4] In 1997, Alteon and Genentech announced a collaboration under which Genentech would fund development of pimagedine and would have the rights to sell the drug if it would be approved. [5]

In March 1998, Alteon announced that it had been advised that it should discontinue its Phase III trial of pimagedine in non-insulin-dependent (type II) diabetes patients with overt nephropathy, after the trial's external safety monitoring committee found an increased risk of side effects in the treatment group. [6] In November 1998, Alteon announced that its Phase III trial for pimagedine as a treatment for end stage renal disease had failed to prove efficacy, which led Carl Gordon, a leading biotech analyst, to say: "It looks like pimagedine is probably finished." [7] In February, 1999, Genentech ended its collaboration with Alteon to develop pimagedine. [8] In April 1999 Alteon announced that it would cease development of pimagedine as a treatment for end stage renal disease but might consider continuing development in type 1 diabetic patients with overt nephropathy or progressive kidney disease. [9] Alteon's 2000, 2001, 2002 annual reports indicated that it was not running any clinical trials on pimagedine but was seeking co-development partners. [10] [11] [12] Alteon's 2003 and subsequent annual reports did not mention that Alteon was seeking partners for pimagedine, [13] which indicated that efforts to interest other companies and investors had failed and which signaled that commercial efforts to develop pimagedine as a drug were indeed finished.[ citation needed ]

Chemistry

Synthesis

The industrial synthesis uses the reaction between cyanamide and hydrazine in aqueous solution. [14]

Aminoguanidine synthesis01.svg

The compound can also be obtained from the reduction of nitroguanidine with zinc in acetic acid. [15]

Properties

Aminoguanidine is a colorless solid that is soluble in water and ethanol. It is basic, producing salts when reacted with organic acids. As established by many crystallographic studies, protonation of aminoguanidine occurs at the imino nitrogen. [16] With formic acid, condensation occurs, leading to cyclization to give 3-amino-1,2,4-triazole. [14]

3-Amino-1,2,4-triazole synthesis01.svg

The compound reacts with nitrous acid in acidic medium to give 5-aminotetrazole via the intermediate guanylazide. [14] At neutral pH, the reaction leads to tetrazene. [17] Diazotization in acetic acid yields 1,3-di-(tetrazolyl)-triazene. [14]

5-Aminotetrazole synthesis01.svg

Related Research Articles

<span class="mw-page-title-main">ACE inhibitor</span> Class of medications used primarily to treat high blood pressure

Angiotensin-converting-enzyme inhibitors are a class of medication used primarily for the treatment of high blood pressure and heart failure. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart.

<span class="mw-page-title-main">Pyridoxamine</span> Chemical compound

Pyridoxamine is one form of vitamin B6. Chemically it is based on a pyridine ring structure, with hydroxyl, methyl, aminomethyl, and hydroxymethyl substituents. It differs from pyridoxine by the substituent at the 4-position. The hydroxyl at position 3 and aminomethyl group at position 4 of its ring endow pyridoxamine with a variety of chemical properties, including the scavenging of free radical species and carbonyl species formed in sugar and lipid degradation and chelation of metal ions that catalyze Amadori reactions.

<span class="mw-page-title-main">Exelixis</span> American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars. They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases, such as diabetes, atherosclerosis, chronic kidney disease, and Alzheimer's disease.

DOV Pharmaceutical was a biotechnology company that focused on therapies primarily for central nervous system conditions. It was founded in 1995 by former employees of American Cyanamid, and in 1998 it in-licensed drugs discovered at American Cyanamid for further development. It held an IPO on NASDQ in 2002, and its shares plunged days later after negative details about a past relationship between Élan and DOV emerged.

<span class="mw-page-title-main">Alagebrium</span> Chemical compound

Alagebrium was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic heart failure.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

Tanox was a biopharmaceutical company based in Houston, Texas. The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986 with $250,000, which was a large part of their family savings at that time. Both Changs grew up and received college education in chemistry in National Tsing Hua University in Taiwan and obtained Ph.D. degrees from Harvard University. For postdoctoral training, Tse Wen shifted to immunology and did research with Herman N. Eisen at the Center for Cancer Research, M.I.T. The two Changs successively became research managers and worked with a range of monoclonal antibody projects in Centocor, Inc. based in Malvern, Pennsylvania, from 1981 to 1985. The Changs were recruited by Baylor College of Medicine toward the end of 1985 and offered faculty positions in the Division of Molecular Virology. Soon after their arrival, they were encouraged by a high-ranking Baylor official and local business leaders to start a biotech venture in Houston. This was in a period of time when the economy of Houston was in slump as the result of the collapse of the oil industry.

<span class="mw-page-title-main">Calcium dobesilate</span> Chemical compound

Calcium dobesilate is a vasoprotective. It is the calcium salt of dobesilic acid. It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Switzerland the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of active ingredient.

<span class="mw-page-title-main">Atrasentan</span> Chemical compound

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease.

<span class="mw-page-title-main">Lacosamide</span> Anticonvulsant and analgesic medication

Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.

<span class="mw-page-title-main">Anthony Cerami</span>

Anthony Cerami is an American entrepreneur and medical research scientist.

Delta Funding Corporation (abbreviated to DFC) was a specialty consumer finance company that originated, securitized and sold non-conforming mortgage loans.

<span class="mw-page-title-main">3-Deoxyglucosone</span> Chemical compound

3-Deoxyglucosone (3DG) is a sugar that is notable because it is a marker for diabetes. 3DG reacts with protein to form advanced glycation end-products (AGEs), which contribute to diseases such as the vascular complications of diabetes, atherosclerosis, hypertension, Alzheimer's disease, inflammation, and aging.

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

<span class="mw-page-title-main">Saroglitazar</span> Chemical compound

Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.

Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.

<span class="mw-page-title-main">4-Chlorokynurenine</span> Chemical compound

L-4-Chlorokynurenine is an orally active small molecule prodrug of 7-chlorokynurenic acid, a NMDA receptor antagonist. It was investigated as a potential rapid-acting antidepressant.

Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta, Pfizer and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.

Neurobiological Technologies, Inc. ("NTI") was a biotechnology company that was founded in 1987 by Enoch Callaway and John B. Stuppin to in-license and develop drugs primarily to treat neurological conditions; the company was dissolved in 2009 after the failure of its drug candidate ancrod in a Phase III trial for ischemic stroke.

References

  1. ↑ Thornalley, Paul J. (2003). "Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts". Archives of Biochemistry and Biophysics. 419 (1): 31–40. doi:10.1016/j.abb.2003.08.013. PMID   14568006.
  2. ↑ "Synvista Therapeutics Inc. - BioCentury Company Profiles - BCIQ". BioCentury. Retrieved 2023-05-30.
  3. 1 2 "Alteon 10-K For the fiscal year ended December 31, 1996". Alteon via SEC Edgar. March 27, 1997.
  4. 1 2 Harry Keen; JH Fukker; G Menzinger (July 19, 1997). "Early closure of European Pimagedine trial". The Lancet. PlumX Metrics. 350 (9072): 214–215. doi:10.1016/S0140-6736(97)26029-0. PMID   9250200. S2CID   54316555.
  5. ↑ Barbara Marsh (January 3, 1998). "Biotech's New Watchword: Partnership". Los Angeles Times. Retrieved August 17, 2017.
  6. ↑ "Alteon May Drop Pimagedine In NIDDM". The Pharma Letter. March 19, 1998. Retrieved August 17, 2017.
  7. ↑ "Alteon Shares Plummet On Poor Pimagedine Test Results". San Diego Source. November 16, 1998. Retrieved August 17, 2017.
  8. ↑ http://business.globe24h.com/sec/001/06/060000/0000060271.shtml [ dead link ]
  9. ↑ "Alteon's pimagedine fails primary endpoint". The Pharma Letter. April 12, 1999. Retrieved August 17, 2017.
  10. ↑ https://www.sec.gov/Archives/edgar/data/878903/0000893220-00-000381.txt [ bare URL plain text file ]
  11. ↑ https://www.sec.gov/Archives/edgar/data/878903/000089322001000240/0000893220-01-000240.txt [ bare URL plain text file ]
  12. ↑ https://www.sec.gov/Archives/edgar/data/878903/000089322002000222/0000893220-02-000222.txt [ bare URL plain text file ]
  13. ↑ https://www.sec.gov/Archives/edgar/data/878903/000089322003000272/0000893220-03-000272.txt [ bare URL plain text file ]
  14. 1 2 3 4 Güthner, Thomas; Mertschenk, Bernd; Schulz, Bernd (2006), "Guanidine and Derivatives", Ullmann's Encyclopedia of Industrial Chemistry, American Cancer Society, doi:10.1002/14356007.a12_545.pub2, ISBN   978-3-527-30673-2
  15. ↑ Smith, G. B. L.; Anzelmi, Edward (1935-12-01). "Reduction of Nitroguanidine. III. Synthesis of Aminoguanidine1". Journal of the American Chemical Society. 57 (12): 2730. doi:10.1021/ja01315a510. ISSN   0002-7863.
  16. ↑ Adams, J. M. (1977). "The Crystal Structure of Aminoguanidinium Dihydrogen Orthophosphate". Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry. 33 (5): 1513–1515. Bibcode:1977AcCrB..33.1513A. doi:10.1107/S0567740877006402.
  17. ↑ Patinkin, Seymour H.; Horwitz, Jerome P.; Lieber, Eugene (1955-02-01). "The Structure of Tetracene1,2". Journal of the American Chemical Society. 77 (3): 562–567. doi:10.1021/ja01608a014. ISSN   0002-7863.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.